Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Apr;33(2):211-221.
doi: 10.1007/s40620-019-00677-0. Epub 2019 Dec 18.

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology

Antonio Bellasi  1 , Mario Cozzolino  2 , Fabio Malberti  3 , Giovanni Cancarini  4 , Ciro Esposito  5 , Carlo Maria Guastoni  6 , Patrizia Ondei  7 , Giuseppe Pontoriero  8 , Ugo Teatini  9 , Giuseppe Vezzoli  10 , Marzia Pasquali  11 , Piergiorgio Messa  12 , Francesco Locatelli  13
Affiliations
Practice Guideline

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology

Antonio Bellasi et al. J Nephrol. 2020 Apr.

Abstract

Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.

Keywords: CKD-MBD; Cinacalcet; Etelcalcetide; PTH; Secondary hyperparathyroidism.

PubMed Disclaimer

Conflict of interest statement

Authors were members of an Advisory Board on CKD-MBD supported by Amgen. A.B. reports to have received grants for the participation in scientific meetings from Amgen, Sanofi, Vifor Pharma, and to have received an unrestricted research grant from Amgen. M.C. reports to have received grants for the participation in scientific meetings from Amgen, Shire, Abbvie, Vifor Pharma, Baxter. F.L. reports to have received grants for the participation in scientific meetings from Abbvie, Amgen, Roche, Vifor Pharma. The remaining authors have nothing to report with regard to the present paper.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bellasi A, Mangano M, Galassi A, et al. CKD-MBD, cardiovascular involvement and prognosis. G Ital Nefrol. 2017;34:150–161. - PubMed
    1. Kidney Disease: improving global outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; S1-130 - PubMed
    1. Cozzolino M, Tomlinson J, Walsh L, et al. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs. 2015;20:197–208. doi: 10.1517/14728214.2015.1018177. - DOI - PubMed
    1. Fernandez-Martin JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transpl. 2013;28:1922–1935. doi: 10.1093/ndt/gfs418. - DOI - PubMed
    1. Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10:98–109. doi: 10.2215/CJN.12941213. - DOI - PMC - PubMed

Publication types

MeSH terms